Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, announced the closing of a $60 million Series B financing. This funding, which follows Avenzo's $386 million Series A/A-1 financing announced in November 2024, brings the total capital raised to $446 million.

Avenzo Therapeutics是一家临床阶段的生物技术公司，专注于开发下一代肿瘤治疗方案，宣布已完成6000万美元的B轮融资。此次融资继Avenzo于2024年11月宣布的3.86亿美元A/A-1轮融资之后进行，使得其总融资额达到4.46亿美元。

The proceeds will be used to support the advancement of Avenzo's pipeline of potential best-in-class oncology drug candidates..

这笔资金将用于支持Avenzo潜在的同类最佳肿瘤药物候选管线的进展。

The Series B financing was led by OrbiMed and SR One, with participation from new investor Longwood Fund. All existing investors, including Foresite Capital, Lilly Asia Ventures, Surveyor Capital (a Citadel company), New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, and Quan Capital, participated in this financing..

B轮融资由OrbiMed和SR One领投，新投资者Longwood Fund参与。所有现有投资者，包括Foresite Capital、礼来亚洲基金、Surveyor Capital（Citadel公司）、New Enterprise Associates（NEA）、Deep Track Capital、Sofinnova Investments、Sands Capital、INCE Capital、TF Capital、Delos Capital和Quan Capital，均参与了本轮融资。